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Case Report
Bleomycin induced pneumonitis: a case successfully managed 
with high-dose steroids
Shahid Javed Husain, Ali Bin Sarwar Zubairi, Muhammad Irfan
Section of Pulmonary & Critical Care Medicine, The Aga Khan University Hospital, Karachi.
aIntroduction
Bleomycin is a chemotherapeutic agent used in a
number of solid organ malignancies.1-3 It accumulates in the
skin and lungs resulting in skin ulceration and associated
pulmonary toxicity. Its use is somewhat limited due to its
significant pulmonary adverse effects with bleomycin
induced pnemonitis (BIP) as the commonest and most
dreaded complications. The overall incidence of pulmonary
toxicity is as high as 10% and it is fatal in 1-2%.3,4
We present a case of BIP which was successfully
managed by the aggressive use of high dose steroids with
complete resolution.
Case Report
A 59 year old male with a history of Hodgkin's lym-
phoma which was treated with 6 cycles of ABVD (adri-
amycin, bleomycin, vincristine, doxorubicin) completed
one month ago, presented to the hospital with a 2 week his-
tory of low grade fever and cough accompanied by dysp-
noea and right sided pleuritic chest pain. On physical exam-
ination he was in mild distress. The BP was 110/70 mmHg,
pulse was 100/min, RR 28/min and oxygen saturation of
88% on room air, which increased to 96% on 4 L nasal oxy-
gen. On chest examination he had harsh breath sounds and
crackles at the bases bilaterally. His chest radiograph
showed subtle increase density in both lung bases. He was
started on intravenous ceftriaxone and clarithromycin. A
fibreoptic bronchoscopy with broncho alveoalar lavage was
done. The gram stain and culture sensitivity, acid fast bacil-
li smear and fungal cultures were all negative . The BAL
cell count was not done due to its low specificity.
A high resolution CT scan of chest was performed
which showed diffuse ground glass opacification on both
lower lung zones and pleural based nodules (Figures 1 and 2).
These findings were highly suggestive of bleomycin induced
pneumonitis (BIP). The patient was started on oral steroids at
1 mg/kg (50mg/day). His dyspnoea improved in 48 hours and
he was able to walk to the washroom without assistance and
without  oxygen. He was subsequently discharged home. As
an outpatient he had a spirometry (10 days of steroids) which
showed mildly reduced FVC (70%) and FEV1/FVC ratio of
85%. 
He was continued on steroids which were gradually
tapered down. His dyspnoea resolved completely and he
began to exercise regularly and gained weight as well. A
repeat spirometry after 4 months showed improvement in
FVC to 120% and FEV1/FVC ratio to 71%. Steroids were
discontinued after 6 months and on follow-up he has had no
recurrence. The follow up chest radiograph was also nor-
mal.
Discussion
Bleomycin, originally isolated from the fungus
streptomyces verticillus is an antibiotic agent with antitu-
mor activity.1,2 Bleomycin exerts its antitumor effect by
inducing free radicals leading to tumor cell death and
inhibiting tumor angiogenesis.3 Bleomycin is eliminated
from the body mainly by the kidneys; 60% unchanged in the
first 24 hours; while the rest is deactivated by the enzyme
bleomycin hydrolase. Bleomycin is used in several tumor
types such as germ cell tumors, lymphomas, kaposi's sarco-
ma, cervical cancer and head and neck malignancies.
Bleomycin use is somewhat limited due to toxicity
primarily involving the lungs and the skin. Directly after
administration, fever, chills and hypotension are not uncom-
mon, however the most feared and dose limiting side effects
are due to pulmonary toxicity. 
These include Bleomycin induced pneumonitis
(BIP) in 0-46%, bronchiolitis obliterans with organizing
pneumonia and eosiniphilic hypersensitivity. The mortality
associated with BIP is reported in excess of 3% of all
patients treated with bleomycin.4-6
Figure 1. High resolution CT scan of chest showing diffuse ground glass opacification in both
lower lung zones.
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The risk factors suggested include advanced age,
high cumulative dose, renal impairment, bolus administra-
tion, smoking and giving concurrent high flow oxygen and
radiotherapy.6,7 Our patient was an older male who received
only moderate doses of bleomycin  (120 mg/m2), was a non-
smoker and did not receive radiotherapy. Clinically our
patient had a presentation 1 month after the last cycle of
chemotherapy, with a sub acute presentation and typical
physical exam findings and gas exchange abnormalities.4,5
The high resolution CT scan of chest findings of
ground glass opacities and sub pleural nodules and linear
lesions are also characteristic.5,8
Once infection was ruled out by a bronchoscopy,
steroids at high doses were initiated. Clinically our patient
had a very rapid improvement which is uncommon for BIP.
If the BIP is left unchecked it may lead to progressive fibro-
sis and significant morbidity and mortality.4,5 We chose
spirometry to monitor the progress of our patient which
showed a gradual improvement. The treatment was discon-
tinued and the patient on follow-up has not had any recur-
rence of symptoms. 
Conclusion
BIP is not an uncommon complication of bleomycin
related chemotherapy regimen and should always be con-
sidered if the patient presents with compatible features. It
should be treated aggressively due to the significant mor-
bidity associated with it.
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Figure 2. HRCT Chest showing pleural based nodules.
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